ArticleNature communications2020
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 89 citations in OpenAlex.
- Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ERNature medicine · 2026Trial
- Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.Breast cancer research : BCR · 2025Trial
- First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.Journal for immunotherapy of cancer · 2023Trial
- Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Early-life exposure to 27.5 GHz 5G millimeter-wave radiation induces skin-related biological responses in mice.Scientific reports · 2026Article
- Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential.Therapeutic innovation & regulatory science · 2026Review
- Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis.Nature communications · 2026Article
- The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti-HER2 Antibodies and Immunotherapy.Journal of cellular and molecular medicine · 2026Article
- FREM1 serves as a novel therapeutic target in breast cancer through basement membrane-based prognostic modeling with integrated bioinformatics and experimental validation.Discover oncology · 2025Article
- Interaction between the breast tumor microenvironment and gut microbiome.Gut microbes · 2025Review
- Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape.Nature neuroscience · 2025Article
- Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era.Future oncology (London, England) · 2025Article
- Quantifying tumor morphological complexity based on pretreatment MRI fractal analysis for predicting pathologic complete response and survival in breast cancer: a retrospective, multicenter study.Breast cancer research : BCR · 2025Article
- Review
- The Pivotal Role of LACTB in the Process of Cancer Development.International journal of molecular sciences · 2025Review
- RANK/RANKL Signaling Pathway in Breast Development and Cancer.Advances in experimental medicine and biology · 2025Review
- Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer.Frontiers in oncology · 2025Article
- The theoretical impact of AI-based quality evaluation of short-video health information on public cognition and treatment adherence: a case study of denosumab combined with PD-1/PD-L1 therapy for lung cancer bone metastasis.Frontiers in public health · 2025Article
- The pathogenic response of cytotoxic T‑lymphocytes, a common therapeutic target for cancer, has a direct impact on treatment outcomes (Review).Oncology reports · 2024Review
- RANKL/RANK signaling recruits Tregs via the CCL20-CCR6 pathway and promotes stemness and metastasis in colorectal cancer.Cell death & disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 10 institutions in 8 countries.
Clara Gómez-AlezaOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.ORCID 0000-0002-4645-5719
Bastien NguyenBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-6166-4746
Guillermo YoldiOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
Marina CiscarOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
Alexandra BarrancoOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
Enrique Hernández-JiménezOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.ORCID 0000-0002-8232-8151
Marion MaetensBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Roberto SalgadoBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Maria ZafeiroglouOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
Pasquale PellegriniOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
David VenetBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Soizic GaraudMolecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Eva M TrinidadOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.ORCID 0000-0001-6090-5205
Sandra BenítezOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.ORCID 0000-0001-9645-7088
Peter VuylstekeDepartment of Medical Oncology, Université Catholique de Louvain, CHU UCL, Namur, site Sainte-Elisabeth, Namur, Belgium.
Laura PolastroDepartment of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Hans WildiersDepartment of Oncology, KU Leuven-University of Leuven, Leuven, Belgium.ORCID 0000-0001-8990-7837
Philippe SimonDepartment of Obstetrics and Gynaecology, Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Geoffrey LindemanPeter MacCallum Cancer Centre, The Walter and Eliza Hall Institute of Medical Research and The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0001-9386-2416
Denis LarsimontDepartment of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Gert Van den EyndenMolecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Chloé VelgheClinical Trial Supporting Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Françoise RothéBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Karen Willard-GalloMolecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0002-1150-1295
Stefan MichielsService de Biostatistique et D'Epidémiologie, Gustave Roussy, CESP, U1018, Université Paris-Sud, Faculté de Médcine, Université Paris-Saclay, Villejuif, France.ORCID 0000-0002-6963-2968
Purificación MuñozOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
Thierry WalzerCentre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS, Université Claude Bernard, Lyon, France.
Lourdes PlanellesBiOncotech Therapeutics, Parc Cientific Universitat, Valencia, Spain.
Josef PenningerLife Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
Hatem A AzimDivision of Hematology/Oncology, Department of Medicine, American University of Beirut, Beirut, Lebanon.
Sherene LoiPeter MacCallum Cancer Centre, The Walter and Eliza Hall Institute of Medical Research and The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0001-6137-9171
Martine PiccartDepartment of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Christos SotiriouBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. christos.sotiriou@bordet.be.ORCID 0000-0002-5745-9977
Eva González-SuárezOncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain. egonzalez@cnio.es.ORCID 0000-0003-0858-8171
Université Libre de Bruxelles · BEInstitut d'Investigació Biomédica de Bellvitge · ESThe Royal Melbourne Hospital · AUAmerican University of Beirut · LBHighlight Therapeutics (Spain) · ESInstitute of Molecular Biotechnology · ATKU Leuven · BEUCLouvain · BEUniversité Claude Bernard Lyon 1 · FRUniversité Paris-Sud · FR
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Most breast cancers exhibit low immune infiltration and are unresponsive to immunotherapy. We hypothesized that inhibition of the receptor activator of nuclear factor-κB (RANK) signaling pathway may enhance immune activation. Here we report that loss of RANK signaling in mouse tumor cells increases leukocytes, lymphocytes, and CD8
Indexed as
ImmunitySignal TransductionAdultAnimalsBreast NeoplasmsCD8-Positive T-LymphocytesCell Line, TumorChemokinesDenosumabFemaleHumansImmunosuppression TherapyImmunotherapyInflammation MediatorsLymphocytes, Tumor-InfiltratingMice, Inbred C57BLChemokinesDenosumabInflammation MediatorsRANK LigandReceptor Activator of Nuclear Factor-kappa B
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.